These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27679556)

  • 1. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders.
    Navarro G; Morales P; Rodríguez-Cueto C; Fernández-Ruiz J; Jagerovic N; Franco R
    Front Neurosci; 2016; 10():406. PubMed ID: 27679556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacology of cannabinoid receptors and their ligands: an overview.
    Pertwee RG
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
    Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
    Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of cannabinoid signaling in microglia by adenosine A
    Franco R; Reyes-Resina I; Aguinaga D; Lillo A; Jiménez J; Raïch I; Borroto-Escuela DO; Ferreiro-Vera C; Canela EI; Sánchez de Medina V; Del Ser-Badia A; Fuxe K; Saura CA; Navarro G
    Glia; 2019 Dec; 67(12):2410-2423. PubMed ID: 31429130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and functional interaction between GPR18 and cannabinoid CB
    Reyes-Resina I; Navarro G; Aguinaga D; Canela EI; Schoeder CT; Załuski M; Kieć-Kononowicz K; Saura CA; Müller CE; Franco R
    Biochem Pharmacol; 2018 Nov; 157():169-179. PubMed ID: 29870711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.
    Estrada JA; Contreras I
    Curr Neuropharmacol; 2020; 18(8):769-787. PubMed ID: 32065105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.
    Cassano T; Calcagnini S; Pace L; De Marco F; Romano A; Gaetani S
    Front Neurosci; 2017; 11():30. PubMed ID: 28210207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset.
    Shoemaker JL; Seely KA; Reed RL; Crow JP; Prather PL
    J Neurochem; 2007 Apr; 101(1):87-98. PubMed ID: 17241118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.
    Bisogno T; Di Marzo V
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):564-73. PubMed ID: 20632970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol skews biased agonism at cannabinoid CB
    Navarro G; Reyes-Resina I; Rivas-Santisteban R; Sánchez de Medina V; Morales P; Casano S; Ferreiro-Vera C; Lillo A; Aguinaga D; Jagerovic N; Nadal X; Franco R
    Biochem Pharmacol; 2018 Nov; 157():148-158. PubMed ID: 30194918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders.
    Manera C; Arena C; Chicca A
    Recent Pat CNS Drug Discov; 2016; 10(2):142-156. PubMed ID: 27193072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The cannabinoid system and pain: towards new drugs?].
    Beltramo M
    J Soc Biol; 2009; 203(1):99-106. PubMed ID: 19358815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
    Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
    Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
    Fernández-Ruiz J; Romero J; Ramos JA
    Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the endocannabinoid system in drug addiction.
    Manzanares J; Cabañero D; Puente N; García-Gutiérrez MS; Grandes P; Maldonado R
    Biochem Pharmacol; 2018 Nov; 157():108-121. PubMed ID: 30217570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
    Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
    Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoids and neurodegenerative diseases.
    Micale V; Mazzola C; Drago F
    Pharmacol Res; 2007 Nov; 56(5):382-92. PubMed ID: 17950616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.